Abstract # 1784 Neuronal Pentraxin 2 predicts medial temporal atrophy and memory decline across the Alzheimer’s disease spectrum

详细信息    查看全文

• 作者：A. Swanson^a ; A. Willette^a ; ^b ; ^c
• 刊名：Brain, Behavior, and Immunity
• 出版年：2016
• 出版时间：October 2016
• 年：2016
• 卷：57
• 期：supp_S
• 页码：e23
• 全文大小：35 K

文摘

Neuroinflammation is thought to potentiate medial temporal lobe (MTL) atrophy and memory decline in Alzheimer’s disease (AD). It has become increasingly important to find novel immunological biomarkers that can track AD development and progression. Our study examined which pro- and anti-inflammatory cerebrospinal fluid (CSF) biomarkers best predicted AD neuropathology over 24 months. Using Alzheimer’s Disease Neuroimaging Initiative data (N = 285), CSF inflammatory peptides from a mass spectrometry panel were screened with stepwise regression. Linear mixed models regressed selected biomarkers against a memory factor and MTL volume across 24 months. Neuronal Pentraxin 2 (NPTX2) and Chitinase-3-like-protein-1 (C3LP1), biomarkers of synaptic plasticity and microglial activation respectively, were the only significantly selected biomarkers. Higher baseline NPTX2 levels corresponded to less MTL atrophy [R² = .287, p < .001] and substantially less memory decline [R² = .560, p < .001] by month 24. Conversely, higher C3LP1 modestly predicted more MTL atrophy [R² = .083, p < .001] and did not significantly track memory decline over time. In conclusion, NPTX2 is a novel proinflammatory cytokine that performs better than any other immunological biomarker to date, substantially accounting for brain atrophy and especially cognitive decline specific to AD. The microglial biomarker, by contrast, performed modestly. This research may advance the current understanding of AD etiopathogenesis, while expanding early diagnostic techniques by using proinflammatory biomarkers such as NPTX2. Future studies should also see if NPTX2 causally affects MTL morphometry and memory performance.